These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 25002322)

  • 1. Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
    Ward P; Hecht JR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Naeim A
    J Geriatr Oncol; 2014 Oct; 5(4):368-75. PubMed ID: 25002322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
    Naeim A; Ward PR; Wang HJ; Dichmann R; Liem AK; Chan D; Patel R; Hu EH; Tchekmedyian NS; Wainberg ZA; Hecht JR
    J Geriatr Oncol; 2013 Oct; 4(4):302-9. PubMed ID: 24472472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    Tebbutt NC; Wilson K; Gebski VJ; Cummins MM; Zannino D; van Hazel GA; Robinson B; Broad A; Ganju V; Ackland SP; Forgeson G; Cunningham D; Saunders MP; Stockler MR; Chua Y; Zalcberg JR; Simes RJ; Price TJ
    J Clin Oncol; 2010 Jul; 28(19):3191-8. PubMed ID: 20516443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
    Carter HE; Zannino D; John Simes R; Schofield DJ; Howard K; Zalcberg JR; Price TJ; Tebbutt NC
    Eur J Cancer; 2014 Feb; 50(3):535-43. PubMed ID: 24215848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.
    Kroep JR; van Werkhoven E; Polee M; van Groeningen CJ; Beeker A; Erdkamp F; Weijl N; van Bochove A; Erjavec Z; Kapiteijn E; Stiggelbout AM; Nortier HW; Gelderblom H
    J Geriatr Oncol; 2015 Jul; 6(4):307-15. PubMed ID: 26073532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
    Vrdoljak E; Omrčen T; Boban M; Hrabar A
    Anticancer Drugs; 2011 Feb; 22(2):191-7. PubMed ID: 21057306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
    Liu Y; Starr MD; Bulusu A; Pang H; Wong NS; Honeycutt W; Amara A; Hurwitz HI; Nixon AB
    Cancer Med; 2013 Apr; 2(2):234-42. PubMed ID: 23634291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal cancer: AVEX: opportunities in elderly patients with mCRC.
    Hutchinson L
    Nat Rev Clin Oncol; 2013 Nov; 10(11):608. PubMed ID: 24080599
    [No Abstract]   [Full Text] [Related]  

  • 12. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
    Giessen C; Graeven U; Laubender RP; Modest DP; Schulz C; Porschen R; Schmiegel W; Reinacher-Schick A; Hegewisch-Becker S; Stintzing S; Heinemann V
    Ann Oncol; 2013 Dec; 24(12):3051-5. PubMed ID: 24130263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
    Larsen FO; Boisen MK; Fromm AL; Jensen BV
    Acta Oncol; 2012 Feb; 51(2):231-3. PubMed ID: 21936753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
    Hong YS; Jung KH; Kim HJ; Kim KP; Kim SY; Lee JL; Shim BY; Zang DY; Kim JH; Ahn JB; Park YS; Kim TW
    Am J Clin Oncol; 2013 Dec; 36(6):565-71. PubMed ID: 22868243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
    Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
    Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
    Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
    Zhou X; Cella D; Cameron D; Amonkar MM; Segreti A; Stein S; Walker M; Geyer CE
    Breast Cancer Res Treat; 2009 Oct; 117(3):577-89. PubMed ID: 19153829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
    Feliu J; Salud A; Safont MJ; García-Girón C; Aparicio J; Losa F; Bosch C; Escudero P; Casado E; Jorge M; Bohn U; Pérez-Carrión R; Carmona A; Custodio AB; Maurel J
    PLoS One; 2015; 10(1):e0116527. PubMed ID: 25602286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.